Medical College of Wisconsin, Wauwatosa, WI
Maahum Mehdi , Samih Z Thalji , Aditya V. Shreenivas , Sakti Chakrabarti , James P. Thomas , Kathleen K. Christians , Douglas B. Evans , William A. Hall , Beth Erickson , Bicky Thapa , Gulrayz Ahmed , Omid Yazdanpanah , Razelle Kurzrock , Mohammed Aldakkak , Mary Beth Holden , Ben George , Susan Tsai , Carolyn Oxencis , Thomas McFall , Mandana Kamgar
Background: Therapeutic inhibition of constitutive signaling mediated by mutated KRAS in PDAC remains a challenge except for modest success reported with KRAS G12C inhibition. A combinatorial strategy utilizing simultaneous MEK and autophagy inhibition holds therapeutic promise based on mechanism of action and preclinical data. We described characteristics and outcomes of patients (pts) treated with MEK-inh and HCQ at our institution. Methods: Ten KRAS-mutated advanced PDAC pts were treated with trametinib-HCQ (n = 9) or cobimetinib-HCQ (n = 1) off label due to lack of standard treatment options or toxicity concerns with cytotoxic systemic therapy. Trametinib dose was 2 mg once daily orally, Cobimetinib dose was 20 mg BID orally for 3/4 weeks cycles. HCQ was started at 200 mg BID and up-titrated weekly to 600 mg BID. Description of baseline and treatment (tx) characteristics, safety and efficacy is provided. Results: Median age at diagnosis was 61.3 years, and 7 pts were female. The number of prior lines of tx were 0/1/2/3/4 in 3/2/1/2/2 pts, respectively. KRAS mutations were: G12R/G12D/G12V/Q61H in 6/2/1/1 pts. Median overall survival was 6.6 months (m) in all pts, and 6.6/1.7 m in KRAS G12R/other KRAS (p = 0.31). Median progression-free survival was 5.7/6.2/1.5 m in all/KRAS G12R/other KRAS (p = 0.16). Among 8 pts with evaluable response, 1 (12%) had partial response (KRAS G12R) and 4 (50%) stable disease (3/4 KRAS G12R) as best response with disease control rate of 63%/80%/33% in total/KRAS G12R/other KRAS (p = 0.29). Toxicity data are summarized in table 1. Conclusions: MEK-inh-HCQ demonstrated modest efficacy and manageable toxicities among KRAS G12R PDAC pts. Unlike G12D and G12V mutations in the KRAS gene, G12R is defective of conductive interactions for both PI3Ka and NF1. This ultimately results in a weakened signal being shunted through MAPK cascade and provides a unique opportunity where MEK inh can ablate signaling without the alternate pathways and WT-RAS isoforms compensating. Furthermore, as activation of PI3Ka is known to suppress autophagy, its lack of activation by KRAS G12R further sensitizes cells to HCQ. The combination therapy MEK-inh-HCQ is therefore mechanistically-rationale and warrants the further investigation of KRAS G12R as an actionable biomarker.
Grade 1 | Grade 2 | Grade 3 | |
---|---|---|---|
Total | 26 | 17 | 3 |
Skin rash | 6 | 3 | 1 |
Nausea | 5 | 1 | 0 |
Fatigue | 6 | 2 | 0 |
Elevated creatinine | 0 | 3 | 0 |
Abnormal Liver Function Test (LFT) | 3 | 0 | 2 |
Hypoglycemia* | 0 | 2 | 0 |
Anorexia | 2 | 2 | 0 |
Dysgeusia | 1 | 1 | 0 |
Epigastric pain | 0 | 1 | 0 |
Diarrhea | 1 | 1 | 0 |
Headache | 2 | 1 | 0 |
*Among 5 on insulin Maximum tolerated daily dose of HCQ was 800 mg in 6/10 and 1200 mg in 4/10 pts. Dose reduction of trametinib in 2/10 for skin rash Treatment interruption (n = 6): rash (3), elevated creatinine (2), abnormal LFT (2) Treatment discontinuation (n = 1): rash (1)
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Breakthrough
First Author: Gulam Abbas Manji
2021 Gastrointestinal Cancers Symposium
First Author: Alexander Raufi
2022 ASCO Annual Meeting
First Author: Peter J. King
2023 ASCO Annual Meeting
First Author: Andrew H. Ko